Vesigen is pursuing multiple programs through both in-house development and collaborations, currently focusing on the following disease areas:
Current technologies for systemic and topical delivery of ophthalmologic therapies are inefficient and limited by tolerability issues. Vesigen is developing therapeutic programs using ARMMs technology to overcome current limitations and improve options for patients.
Numerous validated intracellular targets in immunology remain undruggable and/or not accessible for gene editing, protein delivery, or RNA interference using existing drug delivery systems. Vesigen has demonstrated high-efficiency in vivo gene editing in difficult-to-reach cell types, paving the way for safer and more efficacious therapeutic interventions.
Delivery to the central nervous system, particularly into neurons, has proven extremely challenging for existing technologies. Vesigen is exploring ARMMs-based therapeutic programs targeting neurological diseases for which there are no available treatments.
Current disease-modifying strategies to treat hematological disorders require frequent dosing or complex treatment regimens. We are engineering ARMMs to address hematological diseases through targeted in vivo delivery of therapeutic payloads to hepatic and extra-hepatic cell types, with the aim of producing durable, best-in-class medicines for patients.
Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139
